Imaging and diagnostics is fast becoming one of the most effective means of detecting cancer. In recent years, CRT has expanded its licensing portfolio in this arena, facilitated by significant investment and funding from Cancer Research UK.

Cancer Research UK and the Engineering and Physical Sciences Research Council (EPSRC) have led an exciting strategic initiative to establish the UK as a world leader in cancer imaging research. Cancer Research UK alone has committed to an investment of up to £30 million.

As a result of such investment, four large imaging centres have been set up across the UK at:

• Imperial College London
• The Institute of Cancer Research
• A joint centre between Kings College London and University College London
• The University of Oxford

In addition, five cancer imaging research programmes have been set up at:

• The Childhood Cancer and Leukaemia Group (CCLG) at The University of Birmingham
• The Royal Surrey County Hospital
• The University of St Andrews
• Newcastle University
• The University of Sheffield

CRT, by way of the charity, has exclusive commercialisation rights to any Intellectual Property arising from these centres and programmes. CRT Business Managers work closely with the Centre Leaders and Programme Leaders to establish the best commercial model to ensure new discoveries become available to cancer patients.

Cancer Research UK additionally runs a scheme – Biomarkers & Imaging Discovery & Development Committee (BIDD) – which reviews and funds biomarker and imaging research from scientists, clinicians or healthcare workers in UK universities, medical schools, hospitals and some research institutions.

CRT Business Managers are actively involved in the evaluation of BIDD applications. CRT, by way of the charity, has exclusive commercialisation rights to any Intellectual property arising from these programmes.

Find out how to apply for BIDD funding here.

For more information please contact CRT

+44 (0) 20 3469 6300 enquiries@cancertechnology.com